The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture

• Published in: Turk oftalmoloji gazetesi Vol. 48; no. 4; pp. 190 - 195
• Main Authors: Şahiner, Mustafa, Bahar, Dilek, Öner, Ayşe, Gönen, Zeynep Burçin, Ünlü, Metin, Gülmez Sevim, Duygu, Karaca, Çağatay, Mirza, Galip Ertuğrul
• Format: Journal Article
• Language: English
• Published: Turkey Galenos Yayinevi Tic. Ltd 01-08-2018; Türk Oftalmoloji Derneği; Galenos Publishing House; Galenos Publishing; Galenos Yayinevi
• Subjects: Anti-VEGF; Apoptosis; Cell culture; Comparative analysis; Drugs; Metabolism; Monoclonal antibodies; Morphology; Original; Oxidative stress; Permeability; Proteins; Rabbits; Retina; retinal pigment epithelial cell; Senescence; Statistical analysis; Tıp; Vascular endothelial growth factor; İstanbul; Türkiye; United States > US; Japan; Germany; senescence; Anti-VEGF; retinal pigment epithelial cell; cell culture
• ISSN: 2149-8695; 1300-0659; 2147-2661; 2149-8709
• DOI: 10.4274/tjo.20270

To assess the effects of anti-vascular endothelial growth factor (VEGF) drugs on retinal pigment epithelium cell culture.
Aflibercept (0.5 mg/mL), bevacizumab (0.3125 mg/mL), and ranibizumab (0.125 mg/mL) were applied to retinal pigment epithelium cell cultures isolated from the enucleated eyes of New Zealand white rabbits. Viability, apoptosis, proliferation, and senescence of the cells were evaluated in control and drug-treated cultures at the end of 72 hours.
Cells treated with aflibercept showed increased viability and decreased apoptosis compared to the control culture and both the bevacizumab- and ranibizumab-treated groups (p<0.05). Statistically increased apoptosis and decreased viability were found in the bevacizumab and ranibizumab-treated groups compared with the control group (p<0.05). There were no statistically significant differences in cell proliferation and senescence between the groups (p>0.05).
Anti-VEGF drugs did not affect senescence or proliferation of retinal pigment epithelium cells. Aflibercept was found to decrease apoptosis and increase cell viability, while ranibizumab and bevacizumab increased apoptosis and reduced cell viability in retinal pigment epithelium culture.